Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Furosemide | Furosemide may increase the ototoxic activities of Bekanamycin. |
| Magnesium | The serum concentration of Magnesium can be decreased when it is combined with Bekanamycin. |
| Vibrio cholerae CVD 103-HgR strain live antigen | The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Bekanamycin. |
| Estetrol | The therapeutic efficacy of Estetrol can be decreased when used in combination with Bekanamycin. |
| Cefepime | The risk or severity of ototoxicity and nephrotoxicity can be increased when Cefepime is combined with Bekanamycin. |
| Lidocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Lidocaine. |
| Ropivacaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Ropivacaine. |
| Bupivacaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Bupivacaine. |
| Cinchocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Cinchocaine. |
| Dyclonine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Dyclonine. |
| Procaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Procaine. |
| Prilocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Prilocaine. |
| Proparacaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Proparacaine. |
| Meloxicam | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Meloxicam. |
| Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Oxybuprocaine. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Cocaine. |
| Mepivacaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Mepivacaine. |
| Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Levobupivacaine. |
| Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Diphenhydramine. |
| Benzocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Benzocaine. |
| Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Chloroprocaine. |
| Phenol | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Phenol. |
| Tetrodotoxin | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Tetrodotoxin. |
| Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Benzyl alcohol. |
| Capsaicin | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Capsaicin. |
| Etidocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Etidocaine. |
| Articaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Articaine. |
| Tetracaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Tetracaine. |
| Propoxycaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Propoxycaine. |
| Pramocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Pramocaine. |
| Butamben | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Butamben. |
| Butacaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Butacaine. |
| Oxetacaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Oxetacaine. |
| Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Ethyl chloride. |
| Butanilicaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Butanilicaine. |
| Metabutethamine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Metabutethamine. |
| Quinisocaine | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Quinisocaine. |
| Cisatracurium | Bekanamycin may increase the neuromuscular blocking activities of Cisatracurium. |
| Mesalazine | The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Bekanamycin. |
| Capecitabine | Capecitabine may increase the nephrotoxic activities of Bekanamycin. |
| Olsalazine | The risk or severity of nephrotoxicity can be increased when Bekanamycin is combined with Olsalazine. |
| Ambroxol | The risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Ambroxol. |
| Fecal microbiota | The therapeutic efficacy of Fecal microbiota can be decreased when used in combination with Bekanamycin. |
| Oxaliplatin | The risk or severity of nephrotoxicity can be increased when Oxaliplatin is combined with Bekanamycin. |
| DaxibotulinumtoxinA | Bekanamycin may increase the neuromuscular blocking activities of DaxibotulinumtoxinA. |
| Inotersen | The risk or severity of nephrotoxicity can be increased when Inotersen is combined with Bekanamycin. |